NCT07890909
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Notable Recruitment opened
- Start date pushed from Oct 23, 2026 to Nov 13, 2026
- Study sites: 1 to 2
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date: Oct 23, 2026 to Nov 13, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from Baseline in the Self-Injection Administration Questionnaire (SIAQ) Scores at Week 12 After Transitioning to Povetacicept Injection
Timeframe: Baseline up to Week 12
Secondary (1)
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Arms and interventions
PovetaciceptExperimental
Participants previously receiving Sibeprenlimab will self-administer Povetacicept.
Drugs: Povetacicept, Sibeprenlimab
Sites
2 sites in 1 country